Universal versus guideline-based germline multigene panel testing in solid tumors: Diagnostic yield, variant of uncertain significance burden, and clinical actionability - A systematic review with meta-analysis
Publication date: Available online 24 September 2026 Source: Genetics in Medicine Author(s): Imad Barjij, Sarah Naciri, Sihame Lkhoyaali, Saoussane Kharmoum, Hanane Inrhaouen, Ibrahim Elghissassi, Saber Boutayeb, Hind Mrabti, Hassan Errihani
Universal versus guideline-based germline multigene panel testing in solid tumors: Diagnostic yield, variant of uncertain significance burden, and clinical actionability - A systematic review with meta-analysis. // Genetics in Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S1098360026010518?dgcid=rss_sd_all
Universal versus guideline-based germline multigene panel testing in solid tumors: Diagnostic yield, variant of uncertain significance burden, and clinical actionability - A systematic review with meta-analysis. Genetics in Medicine. https://www.sciencedirect.com/science/article/pii/S1098360026010518?dgcid=rss_sd_all
“Universal versus guideline-based germline multigene panel testing in solid tumors: Diagnostic yield, variant of uncertain significance burden, and clinical actionability - A systematic review with meta-analysis.” Genetics in Medicine.
@article{article47068,
title = {Universal versus guideline-based germline multigene panel testing in solid tumors: Diagnostic yield, variant of uncertain significance burden, and clinical actionability - A systematic review with meta-analysis},
journal = {Genetics in Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S1098360026010518?dgcid=rss_sd_all}
}
ABSTRACT Very long‐chain acyl‐CoA dehydrogenase deficiency (VLCADD) is an autosomal recessive disorder of mitochondrial fatty acid β ‐oxidation caused by biallelic pathogenic variants in ACADVL. Its most severe form, the cardiomyopathic...